Cargando…

Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients—A prospective observational study

INTRODUCTION: COVID‐19 infection is associated with high mortality among hemodialysis patients. Standard vaccine response is generally lower among these patients. The adequate antibody titer response and the outcome of COVID‐19 vaccine responders versus non‐responders are unknown. METHODS: Hemodialy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al‐Muhaiteeb, Abdullah, AlSahow, Ali, Al‐Yousef, Anas, AlHelal, Bassam, Alrajab, Heba, Bahbahani, Yousif, dewidar, Noha, Fanous, George N. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304137/ https://www.ncbi.nlm.nih.gov/pubmed/34989097 http://dx.doi.org/10.1111/hdi.13005

Ejemplares similares

POS-923 RESPONSE TO AND OUTCOMES OF THE Pfizer BNT162B2 VACCINE IN HEMODIALYSIS PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY
por: AlMuhaiteeb, A., et al.
Publicado: (2022)

Impact of COVID-19 infection on the dialysis population prospective, observational, nationwide study
por: AlSahow, Ali, et al.
Publicado: (2022)

Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study
por: AlSahow, Ali, et al.
Publicado: (2022)

Glomerulonephritis Histopathological Pattern Change
por: AlYousef, Anas, et al.
Publicado: (2020)

POS-839 CCOVID-19-Associated vs. Non-COVID-19-Associated Acute Kidney Injury: A Prospective, Observational Multi-Center Study
por: Al Sahow, A., et al.
Publicado: (2022)

Moderate stepwise restriction of potassium intake to reduce risk of hyperkalemia in chronic kidney disease: A literature review
por: AlSahow, Ali
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis
por: Wahlen, Bianca Maria, et al.
Publicado: (2022)

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
por: Al-Rasbi, Sara, et al.
Publicado: (2022)

A retrospective evaluation of side‐effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID‐19 vaccine among females in Eastern Province, Saudi Arabia
por: Hassan, Yousif A.M., et al.
Publicado: (2022)

Kt/V: achievement, predictors and relationship to mortality in hemodialysis patients in the Gulf Cooperation Council countries: results from DOPPS (2012–18)
por: AlSahow, Ali, et al.
Publicado: (2020)

Diabetes Prevalence, Treatment, Control, and Outcomes Among Hemodialysis Patients in the Gulf Cooperation Council Countries
por: Al-Ghamdi, Saeed M.G., et al.
Publicado: (2022)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
por: Yong, Shin-Jie, et al.
Publicado: (2022)

A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine
por: Al-Maqbali, Juhaina Salim, et al.
Publicado: (2021)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

POS-940 ANTIBODY RESPONSE TO PFIZER BNT162b2 VACCINE IN HEMODIALYSIS PATIENTS: THE PREVIOUS SARS-CoV-2 INFECTION INFLUENCE
por: FREITAS, M., et al.
Publicado: (2022)

Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
por: Al-Matouq, Jenan Ahmed, et al.
Publicado: (2022)

Editorial: Advances in chronic kidney disease diagnosis and therapy
por: Ali, Hamad, et al.
Publicado: (2023)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
por: Altermanini, Mohammad, et al.
Publicado: (2023)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS
por: BEIRÃO, B., et al.
Publicado: (2022)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman
por: Alhashim, Ali, et al.
Publicado: (2022)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gperv7un2u119adb9sdmoluhkp